ArticleTranslational oncology2026
Clinicopathologic and molecular features of primary effusion lymphoma and fluid overload-associated large B-cell lymphoma: A retrospective study.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary effusion lymphoma (PEL) and fluid overload-associated large B-cell lymphoma (FO-LBCL) are rare B-cell neoplasms presenting as serous effusions without solid masses, distinguished primarily by human herpesvirus-8 status. We analyzed three PEL and seven FO-LBCL cases using immunohistochemistry, Epstein-Barr virus-encoded RNA in situ hybridization, immunoglobulin heavy chain (IGH), T-cell receptor beta (TRB) and T-cell receptor gamma (TRG) gene rearrangement analyses, and targeted next-generation sequencing. The median age was 72 years for PEL and 83 years for FO-LBCL. All PEL cases lacked CD20, whereas FO-LBCL tumors retained pan-B-cell markers. Aberrant T-cell antigen expression was observed in two PEL cases, both showing clonal T-cell receptor rearrangements in addition to IGH clonality. FO-LBCL harbored recurrent alterations involving CD79B, PIM1, and MYD88, suggesting partial molecular overlap with the molecular features characteristic of the MCD subtype of diffuse large B-cell lymphoma (DLBCL). Clinically, all patients with PEL died of disease, whereas FO-LBCL appeared to have a more favorable clinical course, with four patients remaining alive at the last follow-up. Despite morphologic overlap, PEL and FO-LBCL showed distinct immunophenotypic, genetic, and clinical features. These preliminary findings support further investigation of B-cell receptor/NF-κB-related signaling pathways in FO-LBCL and may contribute to improved molecular classification and future therapeutic stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.